New meningitis shot shows promise in teen trial

NCT ID NCT04490018

Completed ⭐️ VACCINE ⭐️ Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times

Summary

This study tested a new meningitis vaccine (MenACYW conjugate vaccine, also called MenQuadfi) in 463 healthy adolescents aged 10 to 17. It compared the new vaccine to an existing one (Nimenrix) and also looked at giving it together with HPV and Tdap-IPV vaccines. The goal was to see if the new vaccine provides similar protection against four types of meningococcal bacteria and is safe to use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Investigational Site Number :3480001

Győr, 9024, Hungary
Investigational Site Number :3480002

Miskolc, 3527, Hungary
Investigational Site Number :3480003

Budapest, 1042, Hungary
Investigational Site Number :3480004

Szigetvár, 7900, Hungary
Investigational Site Number :3480006

Szombathely, 7900, Hungary
Investigational Site Number :3800001

Genova, IT-16132, Italy
Investigational Site Number :3800002

Milan, Lombardy, 20154, Italy
Investigational Site Number :3800004

Palermo, Sicily, 90131, Italy
Investigational Site Number :3800005

Foggia, Apulia, 71122, Italy
Investigational Site Number :3800006

Catanzaro, Calabria, 88100, Italy
Investigational Site Number :7020002

Singapore, 229899, Singapore
Investigational Site Number :7240001

Seville, Andalusia, 41013, Spain
Investigational Site Number :7240002

Barcelona, Barcelona [Barcelona], 08035, Spain
Investigational Site Number :7240003

Madrid, Madrid, Comunidad de, 28007, Spain
Investigational Site Number :7240004

Valencia, Valenciana, Comunidad, 46020, Spain
Investigational Site Number :7240005

Esplugues de Llobregat, Castille and León, 08950, Spain
Investigational Site Number :7240006

Santiago de Compostela, Galicia [Galicia], 15706, Spain
Investigational Site Number :7240007

Puçol, Valenciana, Comunidad, 46530, Spain
Investigational Site Number :7240008

Valencia, Valenciana, Comunidad, 46011, Spain
Investigational Site Number :7240009

Valencia, Valenciana, Comunidad, 46022, Spain
Investigational Site Number :7240010

Valencia, Valenciana, Comunidad, 46022, Spain
Investigational Site Number :7240011

Burriana, Valenciana, Comunidad, 12530, Spain
Investigational Site Number :7240012

Valencia, Valenciana, Comunidad, 46024, Spain

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Meningococcal polysaccharide tetanus toxoid conjugate vaccine (MenACYW, also known as MenQuadfi)

What this could lead to

If successful, this could provide a safe and effective option to protect adolescents against four types of meningococcal disease.

What could go wrong

This trial is complete, but results may not apply to all populations. As with any vaccine, side effects like injection site pain or fever are possible.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS HEALTHY VOLUNTEERS MENINGOCOCCAL IMMUNISATION